⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PRAX News
Praxis Precision Medicines, Inc. Common Stock
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
globenewswire.com
PRAX
Form 8-K
sec.gov
PRAX
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
globenewswire.com
PRAX
Form 8-K
sec.gov
PRAX
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
PRAX
Modified Atmosphere Packaging Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035
globenewswire.com
SEE
PKG
APD
DOW
LIN
PRAX
Form 8-K
sec.gov
PRAX
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
globenewswire.com
PRAX
Form 8-K
sec.gov
PRAX
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
globenewswire.com
PRAX